Takeda Pharmaceutical Company Limited
TAK
$15.46
$0.362.38%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.08B | 30.24B | 30.27B | 29.58B | 29.54B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.08B | 30.24B | 30.27B | 29.58B | 29.54B |
| Cost of Revenue | 10.32B | 10.48B | 10.32B | 10.04B | 9.90B |
| Gross Profit | 19.76B | 19.77B | 19.95B | 19.54B | 19.64B |
| SG&A Expenses | 7.25B | 7.23B | 7.27B | 7.22B | 7.29B |
| Depreciation & Amortization | 3.60B | 3.61B | 3.63B | 3.60B | 3.61B |
| Other Operating Expenses | 404.46M | 288.59M | -175.43M | 352.57M | 218.87M |
| Total Operating Expenses | 26.37B | 26.29B | 25.89B | 26.15B | 26.06B |
| Operating Income | 3.71B | 3.95B | 4.38B | 3.43B | 3.48B |
| Income Before Tax | 1.15B | 1.53B | 1.77B | 306.89M | 414.37M |
| Income Tax Expenses | 437.74M | 165.33M | -152.99M | -668.77M | -601.31M |
| Earnings from Continuing Operations | 710.88 | 1.37K | 1.93K | 975.65 | 1.02K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.41M | -1.20M | -1.14M | -1.14M | -894.20K |
| Net Income | 709.46M | 1.37B | 1.93B | 974.51M | 1.01B |
| EBIT | 3.71B | 3.95B | 4.38B | 3.43B | 3.48B |
| EBITDA | 8.11B | 8.40B | 8.87B | 7.89B | 7.96B |
| EPS Basic | 0.45 | 0.87 | 1.22 | 0.62 | 0.65 |
| Normalized Basic EPS | 1.06 | 1.22 | 1.37 | 0.99 | 1.00 |
| EPS Diluted | 0.44 | 0.85 | 1.21 | 0.62 | 0.65 |
| Normalized Diluted EPS | 1.04 | 1.20 | 1.36 | 0.99 | 0.99 |
| Average Basic Shares Outstanding | 6.32B | 6.31B | 6.29B | 6.27B | 6.26B |
| Average Diluted Shares Outstanding | 6.37B | 6.35B | 6.34B | 6.29B | 6.27B |
| Dividend Per Share | 1.30 | 1.29 | 1.29 | 1.28 | 1.28 |
| Payout Ratio | 277.06% | 143.72% | 101.03% | 199.79% | 198.42% |